QS Investors LLC grew its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 18.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,774 shares of the biopharmaceutical company’s stock after purchasing an additional 13,702 shares during the period. QS Investors LLC’s holdings in Bristol-Myers Squibb were worth $4,891,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in BMY. Renaissance Technologies LLC grew its position in shares of Bristol-Myers Squibb by 108.5% during the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after purchasing an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after purchasing an additional 3,960,191 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares in the last quarter. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Finally, State Street Corp grew its position in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. Hedge funds and other institutional investors own 69.82% of the company’s stock.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $62.42 on Friday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market cap of $102,146.61, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the business earned $0.77 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. equities research analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.56%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
Several research firms recently issued reports on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Jefferies Group reiterated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a research report on Thursday, September 28th. Finally, Cowen set a $65.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $64.93.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/10/qs-investors-llc-has-4-89-million-holdings-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.